Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study
Authors' conclusion
This study suggests that adherent CGM utilization is associated with a significantly lower risk of GLP-1 RA discontinuation and may potentially enhance adherence to GLP-1 RA medication in people living with T2D on nonintensive therapy.
Study context
- Population
- Adults aged ≥18 years with T2D on basal insulin or noninsulin therapy, continuous glucose monitoring (CGM)-naïve before starting GLP-1 RA; Inovalon Insights claims, March 1, 2017, to April 30, 2024matched cohort
- Participants
- 934 vs 3,747
- Exposure
- Adherent CGM use vs no CGM use in adults with T2D starting a GLP-1 RA
- Adherent CGM usersn = 934
- Non-CGM usersn = 3,747reference
- Outcome
- GLP-1 RA discontinuation, defined as the first gap of ≥90 days without GLP-1 RA supply post-index
- Follow-up
- 12-month observation period
Methodological detailsmatched-cohort, administrative claims
- Matched-cohort
- Administrative claims
Main finding
As reported in the abstract
Remained on GLP-1 RA; GLP-1 RA discontinuation (HR) · 1 year post GLP-1 RA initiation
Hazard ratio
0.56
95% CI 0.49–0.63
P < 0.001
By group
Observational data: associations, not effects.
Original publication
Association Between Continuous Glucose Monitoring Utilization and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Type 2 Diabetes: A Real-World Study. Diabetes Technol Ther. Published 19 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →